<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38862619</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [<sup>18</sup>F]FDG-PET study.</ArticleTitle><Pagination><StartPage>3215</StartPage><EndPage>3222</EndPage><MedlinePgn>3215-3222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-024-06775-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">A hypometabolic profile involving the limbic areas, brainstem and cerebellum has been identified in long COVID patients using [<sup>18</sup>F]fluorodeoxyglucose (FDG)-PET. This study was conducted to evaluate possible recovery of brain metabolism during the follow-up of patients with prolonged symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-six adults with long COVID who underwent two brain [<sup>18</sup>F]FDG-PET scans in our department between May 2020 and October 2022 were retrospectively analysed, and compared to 51 healthy subjects. On average, PET1 was performed 7 months (range 3-17) after acute COVID-19 infection, and PET2 was performed 16 months (range 8-32) after acute infection, because of persistent severe or disabling symptoms, without significant clinical recovery. Whole-brain voxel-based analysis compared PET1 and PET2 from long COVID patients to scans from healthy subjects (p-voxel&#x2009;&lt;&#x2009;0.001 uncorrected, p-cluster&#x2009;&lt;&#x2009;0.05 FWE-corrected) and PET1 to PET2 (with the same threshold, and secondarily with a less constrained threshold of p-voxel&#x2009;&lt;&#x2009;0.005 uncorrected, p-cluster&#x2009;&lt;&#x2009;0.05 uncorrected). Additionally, a region-of-interest (ROI) semiquantitative anatomical approach was performed for the same comparisons (p&#x2009;&lt;&#x2009;0.05, corrected).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PET1 and PET2 revealed voxel-based hypometabolisms consistent with the previously reported profile in the literature. This between-group analysis comparing PET1 and PET2 showed minor improvements in the pons and cerebellum (8.4 and 5.2%, respectively, only significant under the less constrained uncorrected p-threshold); for the pons, this improvement was correlated with the PET1-PET2 interval (r&#x2009;=&#x2009;0.21, p&#x2009;&lt;&#x2009;0.05). Of the 14,068 hypometabolic voxels identified on PET1, 6,503 were also hypometabolic on PET2 (46%). Of the 7,732 hypometabolic voxels identified on PET2, 6,094 were also hypometabolic on PET1 (78%). The anatomical ROI analysis confirmed the brain hypometabolism involving limbic region, the pons and cerebellum at PET1 and PET2, without significant changes between PET1 and PET2.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Subjects with persistent symptoms of long COVID exhibit durable deficits in brain metabolism, without progressive worsening.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudouet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, APHM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Jacques-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>CHU Tours, Tours, France, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaphan</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>APHM, Service de M&#xe9;decine interne, Conception Hospital, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radulesco</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Oto-Rhino- Laryngology, Aix-Marseille University, APHM, IUSTI, Conception Hospital, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cammilleri</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;nard</LastName><ForeName>Am&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IHU M&#xe9;diterran&#xe9;e Infection, APHM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guedj</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1912-6132</Identifier><AffiliationInfo><Affiliation>APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Aix-Marseille University, 264 rue Saint-Pierre, Marseille, 13005, France. eric.guedj@ap-hm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2007/09</GrantID><Agency>PHRC</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain PET</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">FDG-PET</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>11</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38862619</ArticleId><ArticleId IdType="doi">10.1007/s00259-024-06775-x</ArticleId><ArticleId IdType="pii">10.1007/s00259-024-06775-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>A clinical case definition of post COVID-19. condition by a Delphi consensus, 6 October 2021 [Internet]. [cited 2022 Oct 24]. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 .</Citation></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48(9):2823&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId><ArticleId IdType="pmc">7837643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, et al. Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. 2021;48(10):3187&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05294-3</ArticleId><ArticleId IdType="pubmed">33677642</ArticleId><ArticleId IdType="pmc">7937050</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A, Barthel H, Tolboom N, Fraioli F, Cecchin D, Albert NL, et al. 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging. 2022;49(11):3599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05913-7</ArticleId><ArticleId IdType="pubmed">35840817</ArticleId><ArticleId IdType="pmc">9286958</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A, Kas A, Dudouet P, Goehringer F, Salmon-Ceron D, Guedj E. Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience. Eur J Nucl Med Mol Imaging. 2022;49(9):3197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05753-5</ArticleId><ArticleId IdType="pubmed">35320385</ArticleId><ArticleId IdType="pmc">8941296</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Dudouet P, Goehringer F, Horowitz T, Kaphan E, Kas A, et al. L&#x2019;hypom&#xe9;tabolisme c&#xe9;r&#xe9;bral en TEP Au 18F-FDG dans Le COVID long. Bull De l&#x2019;Acad&#xe9;mie Nationale De M&#xe9;decine. 2023;207(7):933&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.banm.2023.06.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular Imaging findings on Acute and Long-Term effects of COVID-19 on the brain: a systematic review. J Nucl Med. 2022;63(7):971&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.263085</ArticleId><ArticleId IdType="pubmed">35177424</ArticleId><ArticleId IdType="pmc">9258567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med [Internet]. 2023 Aug 21 [cited 2023 Sep 5]; https://www.nature.com/articles/s41591-023-02521-2 .</Citation></Reference><Reference><Citation>Horowitz T, Doche E, Philip M, Cammilleri S, Suissa L, Guedj E. Regional brain glucose metabolism is differentially affected by ketogenic diet: a human semiquantitative positron emission tomography. Eur J Nucl Med Mol Imaging. 2023;50(7):2047&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-023-06156-w</ArticleId><ArticleId IdType="pubmed">36867201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15(1):273&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2001.0978</ArticleId><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AL, Carli G, Kiferle L, Piersanti P, Palumbo P, Morbelli S et al. Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging [Internet]. 2022 Aug 19 [cited 2022 Oct 31]; https://doi.org/10.1007/s00259-022-05942-2 .</Citation></Reference><Reference><Citation>Blazhenets G, Schr&#xf6;ter N, Bormann T, Thurow J, Wagner D, Frings L et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med [Internet]. 2021/03/31 ed. 2021; https://www.ncbi.nlm.nih.gov/pubmed/33789937 .</Citation></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId><ArticleId IdType="pmc">9046077</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Zhao W, Huang S, Huang Y, Chen Y, Zhang H, et al. Two-year follow-up of brain structural changes in patients who recovered from COVID-19: a prospective study. Psychiatry Res. 2023;319:114969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114969</ArticleId><ArticleId IdType="pubmed">36462292</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, et al. Neuroinflammation after COVID-19 with Persistent Depressive and cognitive symptoms. JAMA Psychiatry. 2023;80(8):787&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2023.1321</ArticleId><ArticleId IdType="pubmed">37256580</ArticleId><ArticleId IdType="pmc">10233457</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz T, Pellerin L, Zimmer ER, Guedj E. Brain fog in long COVID: a glutamatergic hypothesis with astrocyte dysfunction accounting for brain PET glucose hypometabolism. Med Hypotheses. 2023;180:111186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2023.111186</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene C, Connolly R, Brennan D, Laffan A, O&#x2019;Keeffe E, Zaporojan L, et al. Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024;27(3):421&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-024-01576-9</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId><ArticleId IdType="pmc">10917679</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Morbelli S, Kaphan E, Campion JY, Dudouet P, Ceccaldi M et al. From early limbic inflammation to long COVID sequelae [Internet]. Brain. 2021. https://www.ncbi.nlm.nih.gov/pubmed/34142116 .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>